• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol. Immunomic Analysis of the Repertoire of T cell Specificities for Influenza A Virus in Humans.

Giuseppe

Emeritus
J Virol. 2008 Oct 8. [Epub ahead of print]

Immunomic Analysis of the Repertoire of T cell Specificities for Influenza A Virus in Humans.

Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. - Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA; Viral Respiratory Pathogens Research Unit, Departments of Molecular Virology and Microbiology, Baylor College of Medicine, Dallas, Texas; Pharmexa-Epimmune, San Diego, CA.

Continuing antigenic drift allows influenza viruses to escape antibody-mediated recognition and as a consequence, the vaccine currently in use needs to be altered annually.

Highly conserved epitopes recognized by effector T cells may represent an alternative approach for the generation of a more universal influenza vaccine.

Relatively few highly conserved epitopes are currently known in humans, and relatively few epitopes have been identified from proteins other than hemagglutinin and nucleoprotein.

This prompted us to perform a study aimed at identifying a set of human T cell epitopes that would provide broad coverage against different virus strains and subtypes.

To provide coverage across different ethnicities, seven different HLA supertypes were considered.

More than 4000 peptides were selected from a panel of 23 influenza A virus strains based on predicted high-affinity binding to HLA class I or class II and high conservancy levels.

Peripheral blood mononuclear cells from 44 healthy human blood donors were tested for reactivity against HLA-matched peptides in IFNgamma ELISPOT assays.

Interestingly, we found that PB1 was the major target for both CD4(+) and CD8(+) T cell responses.

The 54 non-redundant epitopes (38 class I and 16 class II) identified herein provided high coverage amongst different ethnicities, were conserved in the majority of the strains analyzed, and were consistently recognized in multiple individuals.

These results enable further functional studies of T cell responses during influenza virus infection, and provide a potential base for the development of a universal influenza vaccine.

PMID: 18842709 [PubMed - as supplied by publisher
-
-----
 
Back
Top Bottom